• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可识别的药代动力学模型:额外输入和测量的作用。

Identifiable pharmacokinetic models: the role of extra inputs and measurements.

作者信息

Godfrey K R, Jones R P, Brown R F

出版信息

J Pharmacokinet Biopharm. 1980 Dec;8(6):633-48. doi: 10.1007/BF01060058.

DOI:10.1007/BF01060058
PMID:7229913
Abstract

Single input, single output experiments can result in nonunique solutions for the rate constants to a linear compartmental model used to describe the pharmacokinetics. Where a finite number of solutions exists, a priori knowledge has to be used to distinguish between the solutions. Where there is a infinite number of solutions, assumptions have to be made about the values of some rate constants in order to obtained a unique solution for the other. This paper considers such experiments and determines whether either the addition of an extra input (simultaneously with the first input) or the taking of an extra measurement would result in a unique solution. It is found that perturbing a second input can be useful, but only if the perturbation is of different shape from the first input. Measurements of drug in urine and metabolite in plasma are generally not helpful in resolving identifiability of the drug dynamic model. If a radioactive tracer is used, through, the second measurement (for example, by externally scanning the radioactivity of the liver) can prove useful, but only if the gain of the measuring device is known.

摘要

单输入、单输出实验可能会导致用于描述药代动力学的线性房室模型的速率常数出现非唯一解。在存在有限数量解的情况下,必须利用先验知识来区分这些解。在存在无限数量解的情况下,则必须对某些速率常数的值做出假设,以便为其他常数获得唯一解。本文考虑了此类实验,并确定额外输入(与第一个输入同时进行)或进行额外测量是否会得到唯一解。结果发现,扰动第二个输入可能会有用,但前提是该扰动的形状与第一个输入不同。尿液中的药物和血浆中的代谢物测量通常无助于解决药物动力学模型的可识别性问题。不过,如果使用放射性示踪剂,第二次测量(例如,通过外部扫描肝脏的放射性)可能会有用,但前提是测量设备的增益已知。

相似文献

1
Identifiable pharmacokinetic models: the role of extra inputs and measurements.可识别的药代动力学模型:额外输入和测量的作用。
J Pharmacokinet Biopharm. 1980 Dec;8(6):633-48. doi: 10.1007/BF01060058.
2
Structural identifiability of "first-pass" models.
J Pharmacokinet Biopharm. 1987 Apr;15(2):179-89. doi: 10.1007/BF01062342.
3
Structural identifiability of physiologically based pharmacokinetic models.基于生理的药代动力学模型的结构可识别性。
J Pharmacokinet Pharmacodyn. 2006 Aug;33(4):421-39. doi: 10.1007/s10928-006-9011-7. Epub 2006 Mar 28.
4
Model independent derivation of general equations for the "first-pass" effect and extra-hepatic drug elimination.“首过”效应和肝外药物消除通用方程的模型无关推导。
Eur J Clin Pharmacol. 1977;11(1):57-64. doi: 10.1007/BF00561789.
5
A nonlinear physiologic pharmacokinetic model: I. Steady-state.一种非线性生理药代动力学模型:I. 稳态
J Pharmacokinet Biopharm. 1985 Feb;13(1):73-92. doi: 10.1007/BF01073657.
6
Identifiability in tracer experiments.示踪实验中的可识别性。
Fed Proc. 1980 Jan;39(1):91-6.
7
A general model of metabolite kinetics following intravenous and oral administration of the parent drug.母体药物静脉注射和口服给药后代谢物动力学的一般模型。
Biopharm Drug Dispos. 1988 Mar-Apr;9(2):159-76. doi: 10.1002/bod.2510090205.
8
An identifiability analysis of a parent-metabolite pharmacokinetic model for ivabradine.伊伐布雷定母体-代谢物药代动力学模型的可识别性分析
J Pharmacokinet Pharmacodyn. 2001 Feb;28(1):93-105. doi: 10.1023/a:1011521819898.
9
Drug metabolite kinetics.药物代谢动力学。
Pharmacol Ther. 1981;15(3):521-52. doi: 10.1016/0163-7258(81)90056-5.
10
A minimal input-output configuration for a priori identifiability of a compartmental model of leucine metabolism.用于亮氨酸代谢房室模型先验可识别性的最小输入-输出配置。
IEEE Trans Biomed Eng. 1993 Aug;40(8):797-803. doi: 10.1109/10.238464.

引用本文的文献

1
Classical structural identifiability methodology applied to low-dimensional dynamic systems in receptor theory.经典结构可识别性方法在受体理论中应用于低维动态系统。
J Pharmacokinet Pharmacodyn. 2024 Feb;51(1):39-63. doi: 10.1007/s10928-023-09870-y. Epub 2023 Jun 30.
2
Parameter estimation and uncertainty quantification using information geometry.利用信息几何进行参数估计和不确定性量化。
J R Soc Interface. 2022 Apr;19(189):20210940. doi: 10.1098/rsif.2021.0940. Epub 2022 Apr 27.
3
Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.

本文引用的文献

1
Two-compartment model for a drug and its metabolite: application to acetylsalicylic acid pharmacokinetics.药物及其代谢物的二室模型:在乙酰水杨酸药代动力学中的应用。
J Pharm Sci. 1970 Mar;59(3):364-7. doi: 10.1002/jps.2600590319.
2
On the definition of the compartment concept in pharmacokinetics.关于药代动力学中房室概念的定义
J Theor Biol. 1978 Jul 20;73(2):329-45. doi: 10.1016/0022-5193(78)90194-7.
3
Long-term urinary excretion of methaqualone in a human subject.一名人类受试者中长期甲喹酮的尿液排泄情况。
基于生理学的药代动力学模型在监管提交中的资格认证和报告程序:联合观点。
Clin Pharmacol Ther. 2018 Jul;104(1):88-110. doi: 10.1002/cpt.1013. Epub 2018 Feb 2.
4
Modeling Biphasic Environmental Decay of Pathogens and Implications for Risk Analysis.病原体双相环境衰减建模及其风险分析意义
Environ Sci Technol. 2017 Feb 21;51(4):2186-2196. doi: 10.1021/acs.est.6b04030. Epub 2017 Feb 8.
5
Scale reduction of a systems coagulation model with an application to modeling pharmacokinetic-pharmacodynamic data.系统凝血模型的降尺度及其在药代动力学-药效学数据建模中的应用。
CPT Pharmacometrics Syst Pharmacol. 2014 Jan 8;3(1):e90. doi: 10.1038/psp.2013.67.
6
Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data.在药代动力学建模中结合“自下而上”和“自上而下”方法:将生理药代动力学(PBPK)模型与观察到的临床数据进行拟合。
Br J Clin Pharmacol. 2015 Jan;79(1):48-55. doi: 10.1111/bcp.12234.
7
An approach for identifiability of population pharmacokinetic-pharmacodynamic models.一种群体药代动力学-药效学模型的可识别性方法。
CPT Pharmacometrics Syst Pharmacol. 2013 Jun 19;2(6):e49. doi: 10.1038/psp.2013.25.
8
The design and analysis of parallel experiments to produce structurally identifiable models.平行实验的设计与分析以产生结构可识别的模型。
J Pharmacokinet Pharmacodyn. 2013 Feb;40(1):93-100. doi: 10.1007/s10928-012-9291-z. Epub 2013 Jan 9.
9
Structural identifiability analysis of pharmacokinetic models using DAISY: semi-mechanistic gastric emptying models for 13C-octanoic acid.使用 DAISY 进行药代动力学模型的结构可识别性分析:13C-辛酸的半机理胃排空模型。
J Pharmacokinet Pharmacodyn. 2011 Apr;38(2):279-92. doi: 10.1007/s10928-011-9193-5. Epub 2011 Feb 24.
10
The deterministic identifiability of nonlinear pharmacokinetic models.非线性药代动力学模型的确定性可识别性
J Pharmacokinet Biopharm. 1984 Apr;12(2):177-91. doi: 10.1007/BF01059277.
J Pharmacokinet Biopharm. 1978 Apr;6(2):111-22. doi: 10.1007/BF01117446.
4
Zinc metabolism in humans: a kinetic model.人体锌代谢:动力学模型
Am J Physiol. 1979 Nov;237(5):R340-9. doi: 10.1152/ajpregu.1979.237.5.R340.
5
Adequacy of measurements in compartmental modelling of metabolic systems.
Med Biol Eng Comput. 1979 Mar;17(2):216-22. doi: 10.1007/BF02440932.